RedHill’s Opaganib Drug Wins FDA Orphan Status

RedHill Biopharma (RDHL) has released an update.

RedHill Biopharma Ltd. has announced that their drug opaganib received FDA Orphan Drug Designation for treating neuroblastoma, a serious childhood cancer. This designation promises exclusive marketing and additional benefits like accelerated development, which could be significant given the neuroblastoma market is projected to reach $1.5 billion by the mid-2030s. Opaganib, which is also in development for other oncological and viral diseases, has shown promise in preliminary clinical data and preclinical studies.

For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.